Angiotensin-converting enzyme inhibitors (ACE-Is) prevent target organ damage in several models of hypertension. The aim of this study was to assess the influence of the ACE-
Introduction
Angiotensin-converting enzyme inhibitors (ACE-Is) have been shown to prevent target-organ damage in several models of hypertension. 1, 2 This preventive effect of ACE-Is may be observed in the absence of change in arterial pressure in rats made hypertensive by aortic banding 2 or angiotensin II (Ang II) infusion. 3 In addition, in renal disease of various etiologies, the progression of proteinuria and deterioration of renal function was attenuated by ACE-I but not conventional antihypertensive therapy in rats 4 and man. 5 Such a renal protective effect was observed even when an ACE-I was given in addition to conventional therapy and thus without additional effect on blood pressure (BP). These findings support the concept that the cardiovascular and renal beneficial effects of ACE-Is may be partly independent of their antihypertensive action.
The cardiac beneficial effect of ACE-Is may be related to inhibition of the local generation of the pro-hypertrophic peptide Ang II, acting through stimulation of AT 1 -receptor subtype. 6 In addition to its direct tropic effect, Ang II may be associated with cardiovascular and renal alterations through increased production of reactive oxygen species (ROS). 7 Ang II induces an overexpression of cytosolic proteins involved in the activation of the NAD(P)H oxidase of vascular endothelial and smooth muscle cells, and thus favours the production of ROS, such as superoxide anion, hydrogen peroxide, and hydroxyl radical. 8, 9 Interestingly, manoeuvers that prevented left ventricular hypertrophy and proteinuria associated with chronic Ang II hypertension, such as treatment with the HMG-CoA reductase inhibitor, simvastatin 10 or dietary sodium restriction 11 were accompanied by a reduction of the overproduction of free radicals. These findings strongly suggest that oxidative stress reduction may participate to the beneficial influence of various compounds on target-organ damage associated with long-term Ang II infusion.
In the present study, we tested the hypothesis that the ACE-I, enalapril may not only prevent but also reverse cardiovascular and renal alterations associated with chronic Ang II infusion through reduction of the pro-oxidant effect of the peptide. The effect of enalapril was compared to that of the specific NAD(P)H oxidase inhibitor, apocynin during the developmental (prevention study) and established (intervention study) phases of hypertension induced by chronic Ang II infusion.
Materials and Methods

Animals and Protocol
Male Sprague-Dawley rats (Charles River, L'Arbresle, France) weighing 270 to 320 g were placed in individual metabolic cages and maintained on a regular rat chow with free access to tap water for one week prior to studies. After a three-day baseline period, Ang II (200 ng/kg -1 /min -1 ) was infused subcutaneously via osmotic pumps (model 2002, Alza Corp) for 10 or 17 days in prevention and intervention studies,
respectively. Enalapril (10 mg/kg -1 /day, gavage) or apocynin (600 mg/L in drinking water) were administered 24 hours before and during the 10day period of Ang II infusion in the prevention study or from day 10 to 17 of the Ang II infusion in the intervention study. In a preliminary study it was observed that plasma ACE activity was markedly reduced (from 56±2 to 6±1 IU/L) by the dose of 10 mg/kg -1 /day -1 of enalapril used in the present experiments. Two groups of rats infused with distilled water for 10 or 17 days served as control groups.
Metabolic Parameters
Body weight, food and water consumption, urinary excretion of sodium and potassium were measured daily. Systolic tail-cuff pressure (TCP, Narco Biosystems) measured in conscious rats and urinary excretion of albumin (immunonephelemetry) were determined before and at the end of treatment periods.
Cardiovascular Morphology and Production of Reactive Oxygen Species
At the end of treatment, rats were anaesthetised with sodium pentobarbital (60 mg/kg body weight) and a catheter (PE50) was implanted into the right carotid artery for the measurement of arterial pressure. Blood (1 mL) was then collected, centrifuged and plasma samples were stored at -20°C until measurement of plasma concentration of advanced oxidation protein products (AOPP). The heart was removed and weighed and production of superoxide anion (O 2 0-) by the left ventricle was measured by a chemiluminescence technique using lucigenin, as previously described. 11 Aortic production of O 2 .as well as hydrogen peroxide (H 2 O 2 , luminol and horseradish peroxidase) 11 was determined only in the four groups of the prevention study.
The carotid artery was fixed using neutral buffered formalin (10%, accustain, Sigma) perfused at a constant pressure of 120 mmHg. Carotid arteries were then wax embedded and cross-sectional area (CSA) was measured on hematoxylincoloured slices (10 µm thickness). All procedures were designed in accordance with French law and institutional guidelines for the care and use of laboratory animals.
Biochemical and Statistical Analyses
Plasma concentration of AOPP, considered as an index of protein oxidation, was measured by spectrophotometry (340 nm) using chloramine T, and expressed as mmol/L of chloramine T equivalents. 10 Results were expressed as mean±SE and analysed by one-or two-factor ANOVA for repeated measures as appropriate. Between-group comparisons were detected with the Fisher protected least significant difference test for unpaired values and within-group differences were determined with the Student's t-test for paired values. A p value of less than 0.05 was considered significant. Due to skewed distribution, albuminuria was logtransformed prior to between-group comparison.
Results
Prevention Study
As depicted in Figure 1 , TCP was 125±2 in the control group and 187±5 mmHg after 10 days of Ang II infusion, and was not influenced by enalapril or apocynin (final values of 186±8 and 191±10 mmHg, respectively). Heart weight index and the cross-sectional area of the carotid artery as well as albuminuria were higher by 21, 58 and 285% respectively, in rats infused with Ang II alone when compared to control rats. Enalapril treatment totally prevented the development of cardiac hypertrophy and blunted the increase in CSA and albuminuria induced by Ang II by 43 and 54%, respectively. Apocynin prevented by 44, 43 and 36% respectively, the effect of Ang II on cardiac mass, carotid artery and proteinuria.
As shown in Figure 2 , Ang II-induced hypertension was associated with a 60% increase in superoxide anion production by the left ventricle, and both enalapril and apocynin blunted this effect by 32 and 37% respectively. Plasma concentration of AOPP doubled in response to Ang II, and this effect was limited by 40% in enalapril-and apocynin-treated rats. In response to Ang II infusion, superoxide anion and hydrogen peroxide production by the aorta increased from 0.64±0.06 and 0.59±0.04 to 1.19±0.06 and 1.34±0.09 mV/mg -1 , respectively (p<0.002). The rise in vascular production of reactive forms of oxygen was blunted and to a similar extent (45-55%, p<0.05) by both enalapril and apocynin.
Neither Ang II infusion nor any of the treatment influenced significantly body weight gain, food and water intake. None of the metabolic parameters were significantly affected by Ang II infusion. Enalapril and apocynin reduced potassium excretion without significant changes in serum potassium concentration and in the other metabolic parameters. The rise in sodium excretion and serum concentration associated with Ang II hypertension was abolished by both enalapril and apocynin administration ( Table 1) .
Intervention Study
As depicted in Figure 3 , after 17 days of Ang II infusion, TCP was 200±5 mmHg (129±2 mmHg in vehicle-infused control rats). HWI and CSA of the carotid artery as well as albuminuria increased to a level similar to that achieved after 10 days of Ang II infusion, thus showing that the response of target organs to hypertension reached a steady state after 10 days of Ang II infusion. Neither enalapril nor apocynin, given from day 10 to 17, affected the final level of TCP. However, left ventricular hypertrophy induced by Ang II was reversed by 50-60% by both enalapril and apocynin. The CSA of the carotid artery was not reduced by enalapril, whereas it was lowered by 29% by apocynin. Both enalapril and apocynin partially reversed, and to a similar extent, the rise in albuminuria induced by long-term infusion of Ang II.
Water intake was significantly higher in Ang IIinfused rats compared with control rats (259±24 vs. 209±9 mL/7 days, respectively, p<0.05) and the dipsogenic effect of Ang II was blunted by enalapril but not by apocynin. Urinary excretion of sodium was not significantly affected, whereas potassium excretion was lower and body growth and food consumption were higher in enalapril or apocynin treated rats (Table 1) . No effect of any treatment was detected on plasma concentration of sodium and potassium.
The production of superoxide anion by the heart and the plasma concentration of AOPP were increased to a similar extent after 10 and 17 days of infusion of Ang II; and both enalapril and apocynin normalised these parameters ( Figure 4 ).
Discussion
In the present study, it was demonstrated that ACE inhibition with enalapril not only prevented but also reversed cardiac, vascular and renal alterations associated with hypertension induced by long-term infusion of Ang II. The beneficial effect of enalapril was obtained without significant change in arterial pressure either during the developmental or the established phase of hypertension. Interestingly, the effect of enalapril on target organ damage was accompanied by In the present study, we aimed at evaluating the effect of an ACE-I on target organ damages that develop with Ang II hypertension. Although arterial pressure has a pivotal role, other factors may modulate the cardiovascular and renal alterations. In consideration of previous reports, 3, 12 the Ang II model of hypertension was chosen because ACE inhibition did not affect the development of hypertension induced by longterm infusion of exogenous Ang II. The lack of BP lowering effect of enalapril administered during however, such an effect was not observed in our previous study conducted in the same model. 3 In addition, enalapril was also unable to reduce final arterial pressure in rats with established hypertension (intervention study), although a transitory reduction cannot be excluded. A lack of antihypertensive effect of enalapril in intervention studies was previously described in non-Ang II dependent hypertension such as the DOCA salt hypertension rats. 13 This is at variance with models in which the endogenous formation of Ang II is enhanced, such as renovascular hypertension. In fact, long-term infusion of Ang II is associated with a decrease in plasma renin activity and circulating level of Ang I as well as an increase in plasma concentration of Ang II. 14 Together with the marked inhibition of plasma ACE activity during enalapril administration, these observations suggest that, in this setting, the pressor effect of exogenous Ang II overcame a plausible reduction of endogenous Ang II generation by enalapril. In addition, the present findings indicate that non-angiotensinmediated mechanism(s) that may participate in the pressure lowering effect of ACE-Is could oppose neither the development nor the maintenance of hypertension induced by exogenous Ang II infusion. To our knowledge, no previous study has reported a lack of pressure effect of an ACE-I in established Ang II hypertension as presently described. In addition, the use of the present model of hypertension allows the evaluation of the beneficial effect of ACE-Is on target organ damage beyond reduction of BP.
A major observation of the present experiment was the prevention and regression of Ang IIinduced organ damage by enalapril despite its lack of antihypertensive effect. A non-antihypertensive dose of ramipril was shown to prevent cardiac hypertrophy in rats made hypertensive by aortic banding. 2 At variance with this, enalapril given at the dose of approximately 20 mg/kg -1 /day in the drinking fluid had no effect on the development of cardiac hypertrophy in rats infused with a relatively low (approximately 100 ng/kg -1 /min -1 ) dose of Ang II. 12 In the present study enalapril was administered by gavage and was associated with a 90% inhibition of plasma ACE activity. Enalapril opposed or delayed cardiac hypertrophy and proteinuria in both prevention and intervention studies. In contrast, enalapril partly prevented vascular hypertrophy whereas the carotid artery hypertrophy was not affected by enalapril when given during the established phase of hypertension (from day 10 to 17 of Ang II infusion). In spontaneously hypertensive rats, a reduction in the media thickness of the aorta was observed after a three-month period of administration of various ACE-Is given at non-antihypertensive dose. 15 In the presence of a high level of BP and circulating Ang II, as in the present experiments, a treatment longer than seven days may probably be required for the full expression of the beneficial influence of the ACE-I on vascular structure.
The specific objective of the present experiment was to evaluate the changes in oxidative stress after treatment by enalapril, both in prevention and intervention studies. Ang II-induced target-organ damage may be mediated by overproduction of free radicals 7 subsequently to activation of NAD(P)H oxidase. 8 An interesting finding of the present study was the prevention (in the prevention study) and normalisation (in the intervention study) by enalapril of the Ang II-induced overproduction of superoxide anion by the left ventricle and increase in the plasma concentration of AOPP induced by Ang II. In addition, a BP independent effect similar to that of enalapril on cardiac superoxide anion production and structure was achieved by the specific NADPH oxidase inhibitor apocynin. The absence of effect of oxidative stress reduction on the level of arterial pressure is at variance with the prevention obtained by acetylsalicylic acid in the same model. 16 In the prevention study, enalapril and apocynin similarly blunted the rise in aortic production of free radicals, which was positively correlated with the CSA of the vessel. Although a causal relationship cannot be unequivocally deduced from the present results, these observations suggest that prevention of Ang II- induced superoxide anion generation may mediate the favourable cardiac, vascular and renal effects of ACE inhibition. In a recent study conducted with the same model, prevention of oxidative stress was associated with a lack of increase in BP, cardiac mass and albuminuria. 10 More recently, we demonstrated that the blunting by chronic dietary sodium restriction of the increase in cardiac mass and albuminuria induced by chronic Ang II infusion, independently of an effect on BP, was in fact related to consistent attenuation of superoxide anion generation. 11 It was also reported in rats with aortic binding that high BP could increase superoxide anion production directly or through activation of the local renin-angiotensin system. In addition, the ACE-I captopril reduced superoxide anion production in hypertensive arteries of these rats. 17 Although Ang II was continuously infused and very likely continuously stimulated NAD(P)H oxidase in the present setting, the reduction of free radical production by enalapril may be, at least in part, linked to an inhibition of the local production of Ang II, and thus, blunting of the effect of the peptide on free radicals production. Another possible explanation for the reduced production of free radicals by enalapril is the increase in tissue bradykinin/NO levels. A high level of nitric oxide has been reported to inhibit superoxide generation 18 and participate in the antihypertrophic effects of bradykinin in vitro. 19 Finally, enalapril may attenuate oxidative stress by enhancing the endogenous antioxidant defences as reported in diabetic rats. 20 Beside oxidative stress reduction, the suppression of local Ang II generation and/or increase in tissue bradykinin/NO levels during enalapril administration may have a role in the protective effect of the ACE-I. Despite a high level of circulating Ang II, it was previously reported that cardiac content of Ang II 14 and ACE activity and mRNA 21 were unchanged in rats infused with Ang II. In the kidney, however, chronic infusion of Ang II was associated with an AT 1 -receptor-mediated 22 increase in tissue Ang II 23 together with increase expression angiotensinogen mRNA 24 and increase in renal ACE binding. 25 Another explanation for the effect of the ACE-Is is an accumulation of kinins in the heart, aorta and kidney. 26 Blockade of the bradykinin B 2 -receptor by Hoe140 alleviated the antihypertrophic effect of various ACE-Is in Ang II 3 and aortic coarctation 27 hypertension as well as the antiproteinuric influence of enalapril in rats with passive Heymann nephritis. 28 However, since chronic bradykinin infusion was unable to prevent target-organ damage in Ang II hypertension, 29 it is suggested that kinins may have a beneficial role only in presence of ACE inhibition. The possibility that inhibition of local Ang II formation and/or tissue kinins/NO accumulation participated directly or through oxidative stress reduction in the beneficial effect enalapril cannot be excluded and remains to be demonstrated.
Finally, enalapril may exert its beneficial effect through other factors including changes in volume and sodium homeostasis; however, enalapril had no clear-cut effect on sodium balance in the present studies.
In conclusion, the present work demonstrates that target-organ damage associated with Ang II hypertension can be prevented and also reversed by an ACE-I in absence of BP reduction. 
